Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 188Active not recruiting 56Recruiting 53Terminated 50Unknown 33Withdrawn 15Not yet recruiting 12Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Smoldering Multiple Myeloma 1Multiple Myeloma 1

Interventions

Cisplatin 4130-nm albumin-bound paclitaxel 3camrelizumab 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Laparoscopy 2Bevacizumab 2trilaciclib 1trastuzumab deruxtecan 1toripalimab 1selinexor 1sacituzumab govitecan 1ribociclib 1olaparib 1nimotuzumab 1lenvatinib 1fluorodopa F 18 1durvalumab 1decitabine and cedazuridine drug combination 1dalpiciclib 1cemiplimab 1carfilzomib 1apatinib 1anlotinib 1abemaciclib 1Valacyclovir 1Temozolomide 1Taxes 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Enrolling by invitation × Lenalidomide × Clear all
NCT03815279 2019-08-16

iStopMM

Landspitali University Hospital

Phase 2 Enrolling by invitation
80 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡